These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19627172)

  • 1. Spotlight on sapropterin in primary hyperphenylalaninemia.
    Sanford M; Keating GM
    BioDrugs; 2009; 23(3):201-2. PubMed ID: 19627172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia.
    Sanford M; Keating GM
    Drugs; 2009; 69(4):461-76. PubMed ID: 19323589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sapropterin dihydrochloride for the treatment of hyperphenylalaninemias.
    Blau N
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1207-18. PubMed ID: 23705856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria.
    Burnett JR
    IDrugs; 2007 Nov; 10(11):805-13. PubMed ID: 17968763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study.
    Burton BK; Nowacka M; Hennermann JB; Lipson M; Grange DK; Chakrapani A; Trefz F; Dorenbaum A; Imperiale M; Kim SS; Fernhoff PM
    Mol Genet Metab; 2011 Aug; 103(4):315-22. PubMed ID: 21646032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sapropterin: a new therapeutic agent for phenylketonuria.
    Hegge KA; Horning KK; Peitz GJ; Hegge K
    Ann Pharmacother; 2009 Sep; 43(9):1466-73. PubMed ID: 19654333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sapropterin dihydrochloride: a new drug and a new concept in the management of phenylketonuria.
    Trefz FK; Belanger-Quintana A
    Drugs Today (Barc); 2010 Aug; 46(8):589-600. PubMed ID: 20830319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial.
    Muntau AC; Burlina A; Eyskens F; Freisinger P; De Laet C; Leuzzi V; Rutsch F; Sivri HS; Vijay S; Bal MO; Gramer G; Pazdírková R; Cleary M; Lotz-Havla AS; Munafo A; Mould DR; Moreau-Stucker F; Rogoff D
    Orphanet J Rare Dis; 2017 Mar; 12(1):47. PubMed ID: 28274234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria.
    Blau N; Bélanger-Quintana A; Demirkol M; Feillet F; Giovannini M; MacDonald A; Trefz FK; van Spronsen FJ
    Mol Genet Metab; 2009 Apr; 96(4):158-63. PubMed ID: 19208488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing for tetrahydrobiopterin responsiveness in patients with hyperphenylalaninemia due to phenylalanine hydroxylase deficiency.
    Cerone R; Andria G; Giovannini M; Leuzzi V; Riva E; Burlina A
    Adv Ther; 2013 Mar; 30(3):212-28. PubMed ID: 23436109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guide for diagnosis and treatment of hyperphenylalaninemia.
    Shintaku H; Ohura T; Takayanagi M; Kure S; Owada M; Matsubara Y; Yoshino M; Okano Y; Ito T; Okuyama T; Nakamura K; Matuo M; Endo F; Ida H
    Pediatr Int; 2021 Jan; 63(1):8-12. PubMed ID: 33423362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study.
    Keil S; Anjema K; van Spronsen FJ; Lambruschini N; Burlina A; Bélanger-Quintana A; Couce ML; Feillet F; Cerone R; Lotz-Havla AS; Muntau AC; Bosch AM; Meli CA; Billette de Villemeur T; Kern I; Riva E; Giovannini M; Damaj L; Leuzzi V; Blau N
    Pediatrics; 2013 Jun; 131(6):e1881-8. PubMed ID: 23690520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment.
    Levy H; Burton B; Cederbaum S; Scriver C
    Mol Genet Metab; 2007 Dec; 92(4):287-91. PubMed ID: 18036498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.
    Levy HL; Milanowski A; Chakrapani A; Cleary M; Lee P; Trefz FK; Whitley CB; Feillet F; Feigenbaum AS; Bebchuk JD; Christ-Schmidt H; Dorenbaum A;
    Lancet; 2007 Aug; 370(9586):504-10. PubMed ID: 17693179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria.
    Muntau AC; Adams DJ; Bélanger-Quintana A; Bushueva TV; Cerone R; Chien YH; Chiesa A; Coşkun T; de Las Heras J; Feillet F; Katz R; Lagler F; Piazzon F; Rohr F; van Spronsen FJ; Vargas P; Wilcox G; Bhattacharya K
    Mol Genet Metab; 2019 May; 127(1):1-11. PubMed ID: 31103398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria.
    Vernon HJ; Koerner CB; Johnson MR; Bergner A; Hamosh A
    Mol Genet Metab; 2010 Jul; 100(3):229-33. PubMed ID: 20418136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study.
    Burton BK; Grange DK; Milanowski A; Vockley G; Feillet F; Crombez EA; Abadie V; Harding CO; Cederbaum S; Dobbelaere D; Smith A; Dorenbaum A
    J Inherit Metab Dis; 2007 Oct; 30(5):700-7. PubMed ID: 17846916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sapropterin dihydrochloride use in pregnant women with phenylketonuria: an interim report of the PKU MOMS sub-registry.
    Grange DK; Hillman RE; Burton BK; Yano S; Vockley J; Fong CT; Hunt J; Mahoney JJ; Cohen-Pfeffer JL; ;
    Mol Genet Metab; 2014 May; 112(1):9-16. PubMed ID: 24667082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria.
    Lee P; Treacy EP; Crombez E; Wasserstein M; Waber L; Wolff J; Wendel U; Dorenbaum A; Bebchuk J; Christ-Schmidt H; Seashore M; Giovannini M; Burton BK; Morris AA;
    Am J Med Genet A; 2008 Nov; 146A(22):2851-9. PubMed ID: 18932221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sapropterin. Phenylketonuria: for a minority of patients.
    Prescrire Int; 2010 Jun; 19(107):101-4. PubMed ID: 20738029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.